Bausch + Lomb: clinical trial, pipeline updates for 2021

Yolande Barnard, vice president and general manager of U.S. Pharmaceuticals at Bausch + Lomb, shares an update on the company's latest treatment for patients with DED associated with MGD as well as an investigational drug for the treatment of macular edema associated with uveitis.

See more ASCRS coverage